Evaluating ivosidenib for the treatment of acute myeloid leukemia

References

• Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011 Feb 10;29(5):487–494. PubMed PMID: 21220605; eng.
   PubMed Web of Science ®Google Scholar
• Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015 Sep 17;373(12):1136–1152. PubMed PMID: 26376137; eng.
   PubMed Web of Science ®Google Scholar
• Cancer stat facts: leukemia - acute myeloid leukemia (AML).
   Google Scholar
• Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016 Jan 7;127(1):29–41. PubMed PMID: 26660431; PubMed Central PMCID: PMCPMC4705608. eng.
   PubMed Web of Science ®Google Scholar
• Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013 May 30;368(22):2059–2074. PubMed PMID: 23634996; PubMed Central PMCID: PMCPMC3767041. eng.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016 Jun 9;374(23):2209–2221. PubMed PMID: 27276561; PubMed Central PMCID: PMCPMC4979995. eng.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424–447. PubMed PMID: 27895058; eng.
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Fathi AT, DiNardo CD, et al. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017 Feb;31(2):272–281. PubMed PMID: 27721426.
   PubMed Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009 Sep 10;361(11):1058–1066. PubMed PMID: 19657110; PubMed Central PMCID: PMCPMC3201812. eng.
   PubMed Web of Science ®Google Scholar
• Fathi AT, Wander SA, Faramand R, et al. Biochemical, epigenetic, and metabolic approaches to target IDH mutations in acute myeloid leukemia. Semin Hematol. 2015 Jul;52(3):165–171. PubMed PMID: 26111463; eng.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005 Aug 15;106(4):1154–1163. PubMed PMID: 15870183; eng.
   PubMed Web of Science ®Google Scholar
• Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013 Jun 13;121(24):4854–4860. PubMed PMID: 23591789; PubMed Central PMCID: PMCPMC3682338. eng.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011 Feb 1;29(4):369–377. PubMed PMID: 21172891; eng.
   PubMed Web of Science ®Google Scholar
• Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German acute myeloid leukemia cooperative group. J Clin Oncol. 2009 Jan 1;27(1):61–69. PubMed PMID: 19047294; eng.
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009 Sep 24;361(13):1249–1259. PubMed PMID: 19776406; PubMed Central PMCID: PMCPMC4480917. eng.
   PubMed Web of Science ®Google Scholar
• Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: cancer and Leukemia Group B Study 9222. Blood. 2005 May 1;105(9):3420–3427. PubMed PMID: 15572587; PubMed Central PMCID: PMCPMC1895015. eng.
   PubMed Web of Science ®Google Scholar
• Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018 Oct;93(10):1267–1291. PubMed PMID: 30328165; eng.
   PubMed Web of Science ®Google Scholar
• Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party. Blood. 2018 Mar 22;131(12):1275–1291. PubMed PMID: 29330221.
   PubMed Web of Science ®Google Scholar
• Rao AV. Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):339–347. PubMed PMID: 27913500.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Barosi G, Venditti A, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013 Apr;27(5):997–999. PubMed PMID: 23653072; eng.
   PubMed Web of Science ®Google Scholar
• Thein MS, Ershler WB, Jemal A, et al. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer. 2013 Aug 1;119(15):2720–2727. PubMed PMID: 23633441; PubMed Central PMCID: PMCPMC3821042. eng.
   PubMed Web of Science ®Google Scholar
• Raj RV, Abedin SM, Atallah E. Incorporating newer agents in the treatment of acute myeloid leukemia. Leuk Res. 2018 Nov;74:113–120. PubMed PMID: 30401522; eng.
   PubMed Web of Science ®Google Scholar
• Bohl SR, Bullinger L, Rucker FG. New targeted agents in acute myeloid leukemia: new hope on the rise. Int J Mol Sci. 2019 Apr 23;20(8). PubMed PMID: 31018543; PubMed Central PMCID: PMCPMC6515298. eng. DOI: 10.3390/ijms20081983.
   PubMed Web of Science ®Google Scholar
• Cerrano M, Itzykson R. New treatment options for acute myeloid leukemia in 2019. Curr Oncol Rep. 2019 Feb 4;21(2):16. PubMed PMID: 30715623; eng.
   PubMed Web of Science ®Google Scholar
• Kucukyurt S, Eskazan AE. New drugs approved for acute myeloid leukaemia in 2018. Br J Clin Pharmacol. 2019 Aug 30. PubMed PMID: 31469910; eng. DOI:10.1111/bcp.14105
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019 Jan 3;133(1):7–17. PubMed PMID: 30361262; PubMed Central PMCID: PMCPMC6318429. eng.
   PubMed Web of Science ®Google Scholar
• Xu Q, Li Y, Lv N, et al. Correlation between isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia: a systematic review and meta-analysis. Clin Cancer Res off J Am Assoc Cancer Res. 2017 Aug 1;23(15):4511–4522. PubMed PMID: 28246275; eng.
   PubMed Web of Science ®Google Scholar
• Feng JH, Guo XP, Chen YY, et al. Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. Am J Blood Res. 2012;2(4):254–264. PubMed PMID: 23226625; PubMed Central PMCID: PMCPMC3512179. eng.
   PubMedGoogle Scholar
• Zhou KG, Jiang LJ, Shang Z, et al. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis. Leuk Lymphoma. 2012 Dec;53(12):2423–2429. PubMed PMID: 22616558; eng.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Schimmer AD, Yee KWL, et al. A phase I study of IDH305 in patients with advanced malignancies including relapsed/refractory AML and MDS that harbor IDH1R132 mutations. Blood. 2016;128(22):1073.
   Web of Science ®Google Scholar
• Watts JM, Baer MR, Lee S, et al. A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). J clin oncol. 2018;36(15_suppl):7009.
   Web of Science ®Google Scholar
• Cho YS, Levell JR, Liu G, et al. Discovery and evaluation of clinical candidate IDH305, a brain penetrant mutant IDH1 inhibitor. ACS Med Chem Lett. 2017 Oct 12;8(10):1116–1121. PubMed PMID: 29057061; PubMed Central PMCID: PMCPMC5641959. eng.
   PubMed Web of Science ®Google Scholar
• Chaturvedi A, Herbst L, Pusch S, et al. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. Leukemia. 2017 Oct;31(10):2020–2028. PubMed PMID: 28232670; PubMed Central PMCID: PMCPMC5629366. eng.
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Penas-Prado M, Peters KB, et al. Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma. J clin oncol. 2018;36(15_suppl):2002.
   PubMed Web of Science ®Google Scholar
• Stone RM. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia? Best Pract Res Clin Haematol. 2017 Dec;30(4):312–316. PubMed PMID: 29156201; eng.
   PubMed Web of Science ®Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015 Feb;21(2):178–184. PubMed PMID: 25599133; PubMed Central PMCID: PMCPMC4406275. eng.
   PubMed Web of Science ®Google Scholar
• Yen KE, Bittinger MA, Su SM, et al. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 2010 Dec 9;29(49):6409–6417. PubMed PMID: 20972461; eng.
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009 Dec 10;462(7274):739–744. PubMed PMID: 19935646; PubMed Central PMCID: PMCPMC2818760. eng.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010 Dec 14;18(6):553–567. PubMed PMID: 21130701; PubMed Central PMCID: PMCPMC4105845. eng.
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011 May;12(5):463–469. PubMed PMID: 21460794; PubMed Central PMCID: PMCPMC3090014. eng.
   PubMed Web of Science ®Google Scholar
• Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012 Feb 15;483(7390):474–478. PubMed PMID: 22343901; PubMed Central PMCID: PMCPMC3478770. eng.
   PubMed Web of Science ®Google Scholar
• Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010 Mar 16;17(3):225–234. PubMed PMID: 20171147; PubMed Central PMCID: PMCPMC2849316. eng.
   PubMed Web of Science ®Google Scholar
• Badar T, Kantarjian HM, Nogueras-Gonzalez GM, et al. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol. 2015 Nov;90(11):1065–1070. PubMed PMID: 26299958; PubMed Central PMCID: PMCPMC4618182. eng.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018 Jun 21;378(25):2386–2398. PubMed PMID: 29860938; eng.
   PubMed Web of Science ®Google Scholar
• Kernytsky A, Wang F, Hansen E, et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood. 2015 Jan 8;125(2):296–303. PubMed PMID: 25398940; PubMed Central PMCID: PMCPMC4295919. eng.
   PubMed Web of Science ®Google Scholar
• Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science (New York, NY). 2013 May 3;340(6132):622–626. PubMed PMID: 23558173; eng.
   Google Scholar
• Dai D, Yang H, Nabhan S, et al. Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects. Eur J Clin Pharmacol. 2019 Aug;75(8):1099–1108. PubMed PMID: 31011758; eng.
   PubMed Web of Science ®Google Scholar
• Le K, Wada R, Dai D, et al. Population pharmacokinetics of ivosidenib (AG-120) in patients with IDH1-mutant advanced hematologic malignancies. Blood. 2018;132(Supplement 1):1394.
   Web of Science ®Google Scholar
• Choe S, Wang H, DiNardo CD, et al. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020;4(9):1894–1905.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein AS, Fathi AT, et al. Mutant isocitrate dehydrogenase (mIDH) inhibitors, enasidenib or ivosidenib, in combination with azacitidine (AZA): preliminary results of a phase 1b/2 study in patients with newly diagnosed acute myeloid leukemia (AML). Blood. 2017;130(Supplement 1):639.
   Google Scholar
• Stein E, Dinardo CD, Jang JH, et al. AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation. J clin oncol. 2018;36(15_suppl):TPS7074–TPS7074.
   Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions. Blood. 2018;132(Supplement 1):560.
   Web of Science ®Google Scholar
• Yen K, Chopra VS, Tobin E, et al. Abstract 4956: functional characterization of the ivosidenib (AG-120) and azacitidine combination in a mutant IDH1 AML cell model. Cancer Res. 2018;78(13 Supplement):4956.
   Web of Science ®Google Scholar
• Chopra VS, Avanzino B, Mavrommatis K, et al. Abstract 2280: functional characterization of combining epigenetic modifiers azacitidine and AG-221 in the TF-1: IDH2R140QAML model. Cancer Res. 2016;76(14 Supplement):2280.
   Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016 Oct;6(10):1106–1117. PubMed PMID: 27520294; PubMed Central PMCID: PMCPMC5436271. eng.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 Mar;93(3):401–407. PubMed PMID: 29218851; eng.
   PubMed Web of Science ®Google Scholar
• Norsworthy KJ, Mulkey F, Scott EC, et al. Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis. Clin Cancer Res off J Am Assoc Cancer Res. 2020 May 11. PubMed PMID: 32393603; eng.
   Google Scholar
• Fathi AT, DiNardo CD, Kline I, et al. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study. JAMA Oncol. 2018;4(8):1106–1110.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2019 Dec 16 PubMed PMID: 31841594; eng. DOI:10.1182/blood.2019002140.
   PubMed Web of Science ®Google Scholar
• Norsworthy KJ, Luo L, Hsu V, et al. FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation. Clin Cancer Res off J Am Assoc Cancer Res. 2019 Jun 1;25(11):3205–3209. PubMed PMID: 30692099; eng.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(6):721. English.
   Google Scholar
• Harding JJ, Lowery MA, Shih AH, et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discov. 2018 Dec;8(12):1540–1547. PubMed PMID: 30355724; PubMed Central PMCID: PMCPMC6699636. eng.
   PubMed Web of Science ®Google Scholar
• Intlekofer AM, Shih AH, Wang B, et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018 Jul;559(7712):125–129. PubMed PMID: 29950729; PubMed Central PMCID: PMCPMC6121718. eng.
   PubMed Web of Science ®Google Scholar